For investors to price this biotech at a 6 million dollar EV while competing drugs are at 60-70 million market caps because they are wary of the cholesterol drug is funny
1. 2010 clinical study in genetically modified animals resulted in no adverse effects and de risking the Walter reed study that just started today as well 2. 2024 clinical study resulted in no adverse effects 3. Directors and CEO investing their money in next 4 days at a 15 percent discount to current market price and GLP studies come out next month tells you what they already know
Funny being Wary and pricing in nothing for this Biotech. Severely undervalued and should be at a 70 million market cap with the cash it also has on hand and once Walter reed results come out will be well north of a 100 million market cap with the US Army investing personally non dilutive funds into the drug. It’s coming
NYR Price at posting:
9.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)